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The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by
modern science-based medicine. Health systems across the world are struggling to
manage it. Added to this struggle are the effects of social confinement and isolation. This
brings into question whether the latest guidelines are relevant in this crisis. We aim to
support urologists in this difficult situation by providing tools that can facilitate decision
making, and to minimise the impact and risks for both patients and health professionals
delivering urological care, whenever possible. We hope that the revised recommenda-
tions will assist urologist surgeons across the globe to guide the management of
urological conditions during the current COVID-19 pandemic.
© 2020 European Association of Urology. Published by Elsevier B.?V. All rights reserved.
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The coronavirus disease 2019 (COVID-19) pandemic is unlike
anything seen before by modern science-based medicine. As
of April 14, 2020, there are 1 933 800 confirmed cases globally
in 210 countries and 120 434 deaths [1]. Health systems
globally have struggled. Anaesthetists and theatre teams have
been redeployed, and intensive care units (ICUs) struggle with
demands as the entire service is refocused on managing the
acutely unwell. Added to this are the effects of social
confinement and isolation. Staff at risk are removed from
the workforce for their own health and some of them get sick,
also limiting capacity. This brings into question whether the
latest guidelines based upon the best evidence and published
only 2 wk ago are relevant in this crisis.
As a scientific society and via the Guidelines, Section
Offices, and the European Urology family of journals, we
believe that it is important that we try to support urologists in
this difficult situation. We aim to do this by providing tools
that can facilitate decision making. Our goal is to minimise the
impact and risks for both patients and health professionals
delivering urological care, whenever possible, although it is
clear that it is not always possible to mitigate them entirely. It
should be understood that there may not be high-quality
evidence for the compromises proposed, but we hope that this
document will function as an important additional guide to
the management of urological conditions during the current
COVID-19 pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), based on the current
European Association of Urology (EAU) guidelines.2. Methods
The Guidelines Office commissioned a Rapid Reaction
Group (GORRG) on March 19, 2020 to facilitate the
development of adapted guidelines, to deal with a range
of situations and priorities. Using the resources of the
Guidelines Office, the panel chairmen, and panel members,
in collaboration with other relevant EAU section offices
plus the Executive Committee, the aim was to ensure an
aligned organisation-wide consensus and response under-
pinned by the best knowledge at our disposal describing
how to react to the urgent crisis impacting urological care
and services.
All recommendations in the guidelines have been
reviewed in light of the COVID-19 pandemic and have been
adapted where appropriate. Panels also had access to and
reviewed a range of national and local COVID-19 guidelines
to ensure complementarity wherever possible. New evi-
dence has been searched for by targeted (nonsystematic)
screening of the available published literature, as well as
including those recently accepted and in press with access
provided by the publisher in strict confidence. The findings
(mostly level 3/4 evidence) were discussed and approved by
panel members across 21 EAU Guideline Panels using
electronic communication. Regarding surgical approach
that applies across several guidelines, it was decided that
the GORRG will provide general recommendations instead
of guideline-specific surgical approach recommendations in
each disease area. All panels were provided the following
specific terms of reference.
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2. Surgical treatment and medical therapy
3. Follow-up/telemedicine (give updated recommenda-
tions on follow-up tailored for the COVID-19 era, with
the aim of limiting as much as possible health care
resources without losing our ability to timely diagnose
disease recurrences/progressions)
4. Emergencies
2.1.2. Levels of priority
Panels were asked to provide tables with recommendations
based on the level of priority, not necessarily covering all
recommendations on the recently published updated EAU
guidelines 2020 [2], but those that the panels felt were
critical drivers of outcome and would especially be
impacted by the current crisis, and always based on the
highest level of evidence that was possible and referenced
whenever possible to maintain a transparent link from
evidence to adapted recommendation. In order to achieve
this, the GORRG produced a colour-coded risk stratification
tool (Table 1) for completion by guideline panels to aid them
with the adaption of their recommendations:
Low priority: clinical harm (progression, metastasis, and
loss of function) very unlikely if postponed for 6 mo (green
colour)
Intermediate priority: cancel but reconsider in case of
increase in capacity (not recommended to postpone for >3
mo): clinical harm (progression, metastasis, and loss of
organ function) possible if postponed for 3 mo, but unlikely
(yellow colour)
High priority: the last to cancel, prevent delay of >6 wk;
clinical harm (progression, metastasis, loss of organ function,
and deaths) very likely if postponed for >6 wk; (red colour)
Emergency: cannot be postponed for >24 h; life threat-
ening—organ function threatening condition (black colour)
2.1.3. Criteria for prioritisation
The criteria established for prioritisation regarding proce-
dure and disease are the following:Table 1 – Levels of priority.
Priority 
category
Low priority Intermediate 
priority
High priority 
Definion Clinical har m very 
unlikely if 
postponed for 6 
mo
Clinical har m 
poss ible if 
postponed for 3– 4 
mo, bu t unli kely
Clinical har m very
if postponed f or  >
A&E = accident and emergency department. Impact of delay on primary outcomes (for instance overall
survival in oncology, cancer-specific survival in oncology,
risk of metastases, and kidney failure for transplant patients)
 Possibility of alternative methods that could replace the
procedure with less operating room requirement
 Presence of comorbidities and/or increased risk of
complications
 Possibility of a threat to patient life if the procedure is not
performed immediately.
 Possibility of a threat of permanent dysfunction of the
organ system if the treatment is not performed
 Probability of a risk of rapidly progressing severe
symptoms that are time sensitive
The criteria derived from COVID-19 pandemic are as follows:
 Current and projected COVID-19 cases in the facility and
region; the final decisions should be made in consultation
with the hospital, surgeon, patient, and other public
health professionals
 Supply of personal protective equipment (PPE) to the
facilities in the system
 Staffing availability
 Bed availability, especially ICU beds
 Availability of adjuvant treatments (ie, chemotherapy)
without which the primary treatment is less/not effective
 Ventilator availability
 Health status and age of the patient, especially given the
risks of concurrent COVID-19 infection during recovery
 Urgency of the procedure
 Risk of bleeding/transfusion—there is a lack of red blood
cell units because blood donors do not go to the hospital.
Co-morbidities such as chronic obstructive pulmonary
disease should be taken into account; patients taking
anticoagulants/antiplatelet therapy (due to increased risk
for transfusion)
 Length of hospitalisation
 Risk of acquiring the COVID infection by the patient
during the treatment course
 Risk of contamination of the staff by asymptomatic but
already positive patient
 Capacity of COVID-19 testing
2.1.4. Peer-reviewing process
Once submissions of adapted recommendations were
received from all 17 EAU Guideline Panels, the GORRG
proceeded with a first round of peer review and ensuredEmergency
 li kely 
6 wk
Life-threatening 
situ ao n; likely to 
have presented via 
A&E despite the 
curr ent pand emic
E U R O P E A N U R O L O G Y 7 8 ( 2 0 2 0 ) 2 1 – 2 824uniformity of the format of recommendations, checked for
consistency, and limited duplication across panel recom-
mendations.
Finally, a second-step peer-reviewing process was done
by seven independent Section Office members (three
experts in oncology and three in nononcology, and one to
comment on both oncology and nononcology); we also
sought peer-review comments from China, given the
significant experience they have had with COVID-19 and
being a few months ahead of Europe in terms of stage of
pandemic and recovery.Table 2 – General recommendations applicable during the COVID-19 p
General recommendations for surgical procedures
 Depending on the resources and capacity, we recommend treating only hi
 Consider not only equipment, OR, and ICU bed capacity, but also blood su
 Consider that even if capacity is available, low-priority patients increase th
 Consider that surgery has been reported to be harmful in asymptomatic 
 Consider treating intermediate-priority patients if capacity is available bu
 Consider older patients with comorbidity at severe risk of COVID infectio
alternative in high-priority cases.
 Where ventilator capacity for COVID patients has been breached, high-p
according to local recommendations—or if unavailable—age and comorbi
 Follow the local recommendations to test staff and patients for COVID, if res
should familiarise yourself with them. Be aware that they may change as
 Follow the local recommendations for personal protective equipment (PPE
Endoscopic Surgeons (SAGES) advise full PPE irrespective of COVID status
 Wear full PPE for COVID-positive patients according to the World Health Or
and virus-proof masks [17,18].
 Intubation and extubation should preferably take place in a negative pre
 All nonessential staff should stay outside the operating room during the 
 Set electrosurgery units to the lowest possible settings to reach the requ
 Avoid or reduce the use of monopolar electrosurgery, ultrasonic dissectors,
 Use, if available, monopolar diathermy handheld devices with attached s
 Clean surgical equipment of COVID-positive or suspected patients separa
General guidance on what to do when faced with a known COVID-19–positiv
COVID-19–negative patients)
 A specially equipped dedicated OR has to be prepared for these cases. For
imaging and an experienced personnel for its handling has to be in the s
 Surgeons and operating team (surgeons, anaesthetists, nurses, technicians, 
OR should be completely protected against infection of COVID-19 and ad
 All minimally invasive procedures should preferably be performed by ex
required should be minimum. Additionally, no external observer is allow
content/uploads/ERUS-guidelines-for-COVID-def.pdf).
 To date, there are no specific data demonstrating an aerosol presence of th
 Smoke evacuation systems with active filtered smoke evacuation mode, cap
be provided during laparoscopic surgeries [16].
 CO2 insufflation should be utilised with a closed system with appropriate
 It should be ensured that 8 mm instruments are not inserted in a 12 m
 It should be ensured that a 5 mm instrument is not inserted in a 12 m
 CO2 insufflation should be turned off and the gas should be vented thr
 Consultation with the CO2 insufflation manufacturer used in your hos
maximal filtration effect.
 The full recommendation of SAGES on this topic as well as the cited 
publication that reports the experience of minimally invasive surgeons 
accessed from the Annals of Surgery [8].
 For (robot-assisted) laparoscopy and retroperitoneoscopy, the lowest al
Insufflation systems is recommended (ERUS) [7].
 It is recommended that electrocautery power setting be lowered as much a
laparoscopic surgery. During access, electrocautery should be provided w
 Evacuation of irrigation fluid during endourological procedures (cystoscopy
through a close system.
General guidance for testing patients before surgery in the COVID-19 periodAfter the second round of peer-review process, different
recommendations have been released and these can be
consulted in 17 guideline topics provided in Supplementary
Tables 1–17.
3. Discussion
The guidance produced is based on expert opinion and
consensus building across the EAU with contributions from
all 250 members of the EAU Guidelines Office and with
contributions from the 130 key opinion leaders forming theandemic.a
gh-priority and emergency cases surgically during the COVID pandemic.
pplies available and drug shortage, in order to prioritise your surgeries.
e footfall and the risk of COVID transmission between patients and staff.
patients who subsequently tested COVID positive [6].
t not during the COVID surge.
n and a fatal outcome. Therefore, carefully balance if surgery is the only
riority surgical candidates requiring ICU ventilation should be triaged
dity.
ources are available. These may differ across hospitals and countries; you
 new information is coming in.
), if resources are available; the Society of American Gastrointestinal and
 of the patient. Familiarise yourself with their recommendation [16,17].
ganization (WHO). This should include double gloves, gowns, face shields,
ssure room if available [19].
procedure.
ired effect.
 and advanced bipolar devices, as these can lead to particle aerosolisation.
moke evacuators.
tely.
e patient needing surgery (these measures are partially also applicable to
 endourology, a mobile C-arm fluoroscopic x-ray system for radiological
pecial OR.
nursing assistants/health care workers, and hospital housekeepers) in the
opt adequate protection devices.
perienced surgeons, and the number of experienced OR staff members
ed in the OR [7] (https://uroweb.org/wp-
e COVID-19 virus released during minimally invasive abdominal surgery.
able of filtering the aerosolised particles from the carbon dioxide, should
 filtering of aerosolised particles:
m da Vinci trocar without a reducer.
m da Vinci trocar even with the reducer in place.
ough a filter prior to specimen extraction.
pital may be necessary to ensure that proper settings are selected for
published evidence can be found on the SAGES website [16]. A recent
from China and Italy in the setting of known/suspected COVID-19 can be
lowed intra-abdominal pressure with the use of intelligent integrated
s possible in order to reduce the surgical smoke production, especially in
ith automatic suction system.
, TURB, BPH, endoscopic surgery, URS, RIRS, and PCNL) should be collected
 Patients with clinical symptoms such as fever and respiratory distress and/or with a travel history to endemic areas and previous contact with COVID-
19 patients should all undergo preoperative COVID-19 test. In an emergency situation, it is suggested that these patients should be handled as COVID-
19–positive patients in order to reduce the risk of contagion for both patients and health care workers.
 Among patients without any clinic symptoms, without a travel history to endemic areas, and without previous contact in the past 2 wk with a COVID-
19–positive patient, testing of elective patients is recommended whenever possible within 48 h prior to surgery in an outpatient clinic setting. One
may consider starting with PCR testing and withholding a chest CT only if the PCR is positive for a COVID-19 infection. However, this might have
severe logistical implications (patients need to visit the hospital repeatedly), and joint testing of PCR and CT may be a more desirable and practical
approach, depending on the local situation. The main reasons for that approach are as follows:
 Patients may be in the incubation period of a COVID-19 infection and subsequently develop COVID-19 postoperatively, placing them at risk for
adverse postoperative outcomes [6].
 Patients may be asymptomatic/mildly symptomatic carriers and shedders of SARS-CoV-2 and place hospital workers at risk, particularly during
intubation and aerosolising procedures.
 Patients may be asymptomatic/mildly symptomatic carriers and shedders of SARS-CoV-2 and place other hospitalised patients at risk, who are
often in higher age groups with comorbidities and at higher risk of severe COVID-19 disease.
 The group is aware that, at present, different triage policies may be applicable depending on the region or country. Even following accounts of the
false negative results of the test and the fact that PPE has to be adopted in all surgical patients, information on the test may be useful in the
postoperative period.
 In addition, we strongly recommend advising patients to comply with general directions regarding social distancing as stated by the government,
since this will likely lower the risk for COVID-19 disease at the time of operation.
General guidance on other assistance aspects beyond surgery
 Telemedicine.
 Potential or proven COVID-19–positive patients must be treated according to local, national, and WHO requirements [18]. In this case, a
comprehensive and robust infection control workflow has to be followed [20].
 A network of expert high-volume centres, at the regional, national, or even supranational level, should guarantee the continuity of the oncological
care in an appropriate way, ensuring the availability of hospital beds and timely management of new patients.
 Remote consultation and a multidisciplinary team are recommended to offer the optimum therapeutics.
 Testing for SARS-CoV-2 should be considered before any high-dose chemotherapy.
 Patients should be guided to get access to nonemergency medical services such as chronic disease treatment online to reduce the number of visitors
in hospitals.
 Patients should be encouraged to take full advantage of digital self-service devices to avoid contact with others, to reduce the risk of cross infections.
BPH = benign prostatic hyperplasia; COVID-19 = coronavirus disease 2019; CT = computed tomography; EAU = European Association of Urology; ERUS = EAU
Robotic Urology Section; ICU = intensive care unit; OR = operating room; PCNL = percutaneous nephrolithotomy; PCR = polymerase chain reaction;
RIRS = retrograde intrarenal surgery; SARS-COV-2 = severe acute respiratory syndrome coronavirus 2; TURB = transurethral resection of the bladder;
URS = ureterorenoscopy.
a Disclaimer: The EAU Guidelines Office COVID-19 recommendations are to support health care systems under severe constrain during the pandemic, but their
application should be modulated according to local pandemic conditions and restrictions in clinical and surgical activity due to local medical directives and
guidance.
E U R O P E A N U R O L O G Y 7 8 ( 2 0 2 0 ) 2 1 – 2 8 25membership of the EAU Section Offices. It is important to
emphasise that during the rapidly evolving COVID-19
pandemic, this guidance may further change and critically
will require adaptation to local resources, health systems,
and specific circumstances of each country or city, bearing
in mind that different countries and indeed different cities
are likely to be at different phases of the pandemic and
national/local health system capacities must dictate the
level of prioritisation implemented in line with local COVID-
19 policies.
In addition, there are some overarching principles that
should be emphasised (as presented in Table 2). In order to
minimise the number of staff who become infected, all
medical personnel should comply with the PPE regula-
tions. If possible, patients should be asked whether they
are at risk of COVID-19 prior to any visit in a practice or
clinic or hospital setting. Patients who are currently known
to be shedding COVID-19 virus should postpone any
investigations of other symptoms unless they are thought
to be life threatening. However, urologists working in
hospitals treating COVID-19 patients may be required to
perform urgent investigations on infected patients. In
these cases, procedures should be performed in dedicated
consultation or operating rooms following the hospitalrecommendation for staff PPE. Even following a negative
COVID-19 test result, it is important to remember the
relatively high risk of a false negative result and, as a
consequence, ensure that all the necessary PPE tools and
general recommendations to reduce COVID-19 transmis-
sion are adequately followed (Table 2) [3]. It is also prudent
during this pandemic, in the absence of extensive
community testing and effective isolation/quarantine
strategies in place, that health professionals perform their
duties on the presumption that all patients they treat are
potentially infected with COVID-19 even if asymptomatic,
given that there is increasing evidence of high infection
rates in asymptomatic individuals in countries conducting
extensive community testing of their citizens [4,5]. In this
regard, it is important to consider the risk not only for staff
but also for the patients. Recent evidence from Wuhan
reported a 20% mortality rate in asymptomatic patients
who tested COVID positive after the surgical procedure
[6]. Onset of symptoms was within 2.6 d, and 44.1%
required ICU support. Out of 20 asymptomatic COVID-
positive patients undergoing level 3 complexity proce-
dures, which are equivalent to urological transabdominal
or retroperitoneal interventions, seven died in ICU from
acute respiratory distress syndrome (Table 2).
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mended that all procedures should be performed by
experienced urologists confident in the procedure. They
should be performed with the minimum number of staff
members, who should also be fully trained and experienced.
Furthermore, no external observers should be present
during the procedure (ie, fellows or students) [7]. Use of
ultrasonic scalpels or electrical equipment producing
surgical smoke should be discouraged because such smokes
could carry the COVID-19 [8]. In previous studies, activated
Corynebacterium, papillomavirus, and human immunodefi-
ciency virus (HIV) have been detected in surgical smoke,
and several doctors contracted a rare papilloma virus
suspected to be connected to surgical smoke exposure.
There is no reason to suppose that COVID-19 infection could
not be spread in the same way. One study found that after
using electrical or ultrasonic equipment for 10 min, the
particle concentration of the smoke in laparoscopic surgery
was significantly higher than that in traditional open
surgery [8]. Thus, it is recommended to lower electrocau-
tery power settings as much as possible. There is no
conclusive evidence regarding the differences in risks of
open versus laparoscopic surgery for the surgical team.
However, laparoscopic surgery may be associated with a
higher amount of smoke particles than open surgery [9]. On
the contrary, minimally invasive surgery has the benefit of
reducing the length of hospital stay and reducing the risks
to the patient for contracting COVID-19 whilst in hospital.
During laparoscopy, surgical smoke is released into theatre
under pressure at several stages of surgery. It is advisable to
keep intraperitoneal pressure as low as possible and to
aspirate the inflated CO2 as much as possible before
removing the trocars (Table 2) [7–9].
The duration and frequency of shedding of COVID-19
virus in urine are unknown [10]. However, a recent study by
Ling et al [11] reported limited persistence of SARS-CoV-2
nucleic acid in urine. These data do not prove a link between
urine spillage and virus transmission. However, although no
evidence of disease transmission through urine is demon-
strated yet, urine sampling (for urine culture, dipsticks, and
other analyses), urethral catheterisation, and endoscopic
procedures (eg, transurethral resection of the prostate,
transurethral resection of the bladder, ureteral stenting,
etc.) should be executed with caution. As spills are
inevitable, surfaces should be cleaned rapidly by using
appropriate absorbent and by decontamination with
chlorine (5000–10 000 mg/l) or another appropriate disin-
fectant (note that chlorhexidine is ineffective against
COVID-19 and is not appropriate) [12]. Spills should be
handled according to local guidelines. Similarly, in case of
spillage leading to unwanted contact (ie, accidental expo-
sure) with a member of the staff, appropriate measures
should be taken following local protocols.
It is now clear that SARS-CoV-2 is present in the stools of
COVID-19 patients. Therefore, the transmission during
various procedures (eg, transrectal prostate biopsy and
urinary diversions) might be possible [13]. Therefore, even if
clear evidence of COVID-19 virus spreading through faecesis not demonstrated yet, it is preferable to minimise the
risks of faecal transmissions.
Social distancing is the key player to fight against COVID-
19 pandemic. We have a duty to avoid unnecessary
outpatient visits and in doing so reduce the chance of virus
transmission. Increasing use of telehealth may be an
important way to continue to support patients and their
carers during this crisis. It will be interesting to see if this
change, born of necessity, is incorporated into urological
practice beyond the pandemic (Table 2) [14,15].
While it cannot be predicted when we will be able to
revert back from the acute phase of the COVID-19 pandemic
and resume more normal levels of urological care, we need
to plan ahead on how the urological community should do
this.
The most logical step will be to reverse back through the
aforementioned prioritisation stages. During this process,
we will need to confer with our fellow surgical (sub)
specialities to prioritise the available surgical time and
resources among all surgical patients.
Undoubtedly there will be cases where the optimal
surgical treatment time point will be surpassed. These
patients may be at risk of a suboptimal outcome or an
increased psychological burden due to delayed surgery, and
should be prioritised in the long waiting lists that we will
undoubtedly be facing on the other end of this crisis.
4. Conclusions
The EAU is a family of 19 000 members, and beyond our
membership, the EAU feels a huge sense of responsibility
towards each and every urologist globally, wherever they
may be, appreciating that the EAU guidelines are now
endorsed by national societies of 72 countries. This
extended family ethos is even more important at a time
like this when we are acutely aware of the despair that
nations and their citizens are experiencing around the
world. For instance, we realise that our colleagues and
friends in Italy, Spain, France, UK, other EU member states
and increasingly in the USA are being particularly impacted,
whilst on the other side of the world, our friends in China,
South Korea, and Japan look to rebuild and return to some
form of new normality. Our thoughts are with each and
every one of you. Despite these incredibly difficult times,
key opinion leaders across the breadth of our membership
have come together like never before to rapidly produce this
publication on adapting EAU guideline recommendations to
COVID-19 that we hope will fill an important urological
practice void and assist urologist surgeons across the globe
as they do their very best to deal with the crisis of our
generation.
The EAU Guidelines Office COVID-19 recommendations
can be consulted in Supplementary Tables 1–17.
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